145599-86-6

Basic information

• Product Name: CERIVASTATIN SODIUM
• Synonyms: RIVASTATIN;sodium 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-dipropan-2-yl-pyrid in-3-yl]-3,5-dihydroxy-hept-6-enoate;LIPOBAY;BAYCOL;CERIVASTATIN NA;CERIVASTATIN, SODIUM SALT;7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-dipropan-2-yl-pyrid in-3-yl]-3,5-dihydroxy-hept-6-enoate;(3R,5S,6E)-7-[4-(p-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl]-3,5-dihydroxy-6-heptenoic acid
• CAS NO: 145599-86-6
• Molecular Formula: C₂₆H₃₄FNO₅
• Molecular Weight: 481.53
• Product Categories: Active Pharmaceutical Ingredients
• Mol File: 145599-86-6.mol

Chemical Properties

• Boiling Point: 646.3 °C at 760 mmHg
• Flash Point: 344.7 °C
• Appearance: /
• Density: 1.181 g/cm3
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.594
• Storage Temp.: Hygroscopic, -20°C Freezer, Under Inert Atmosphere
• Solubility: Ethanol (Slightly), Methanol (Slightly), Water (Slightly)
• PKA: pKa 4.38 (H2O t=25 I=0.025) (Uncertain);5.29(H2O t=25 I=0.025) (Uncertain)
• Stability: Hygroscopic
• CAS DataBase Reference: CERIVASTATIN SODIUM(CAS DataBase Reference)
• NIST Chemistry Reference: CERIVASTATIN SODIUM(145599-86-6)
• EPA Substance Registry System: CERIVASTATIN SODIUM(145599-86-6)

Safety Data

• Hazardous Substances Data: 145599-86-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
CERIVASTATIN SODIUM is used as a cholesterol-lowering agent for the treatment of high cholesterol levels and prevention of cardiovascular disease. It works by inhibiting the enzyme HMG-CoA reductase, which is involved in the production of cholesterol in the liver.
Used in Research and Development:
CERIVASTATIN SODIUM is used as a research tool in the study of cholesterol metabolism and the development of new drugs for the treatment of hypercholesterolemia and related conditions. Its withdrawal from the market has also provided valuable insights into the safety and side effects of cholesterol-lowering medications.

InChI:InChI=1/C26H32FNO4/c1-15(2)25-21(11-10-20-12-19(29)13-23(30)32-20)24(17-6-8-18(27)9-7-17)22(14-31-5)26(28-25)16(3)4/h6-11,15-16,19-20,29H,12-14H2,1-5H3/b11-10+/t19-,20-/m1/s1

Relevant articles and documents

Treatment of type 1 diabetes with PDE5 inhibitors

The use of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of Type 1 Diabetes. A method of treating Type 1 Diabetes in an individual suffering from Type 1 Diabetes, which method comprises administering to said individual an effective amount of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof.

Method for producing pharmaceutical dosage forms

The invention relates to a method for producing a granulate while using spray-dried D-mannitol and to the production of pharmaceutical dosage forms comprised of granulates of this type. The invention additionally relates to granulates obtained by using this method and to pharmaceutical dosage forms, which contain statins, especially cerivastatin, and which can be produced from said granulates.